Galderma Group AG
Galderma Group Surges 61% in a Year, Outpacing Swiss Market with FDA Approval
Galderma Group AG’s shares surged 61 % in a year, outpacing Switzerland’s SMI thanks to FDA approval of Restylane Contour and strong investor sentiment—making it a top pick for growth‑focused investors.
3 minutes to read
Galderma Shares Surge 3% on Swiss Exchange, Boosting the SMI
Galderma Group AG’s 3% share rise boosts SMI, showing its strong dermatology portfolio and investor confidence—key for Swiss market gains.
2 minutes to read
Galderma Boosts Dermatology Aesthetics with Sculptra, Restylane Trials & New ALASTIN Signature Launch
Galderma’s new Sculptra & Restylane trials show lasting volume boost for menopausal & weight‑loss patients, while its ALASTIN Signature Practice rollout aims to elevate peri‑procedural care in the US.
2 minutes to read
Galderma’s MDR Certification & S&P Upgrade Spark Investor Confidence, Fueling Aesthetics Growth
Galderma’s Sculptra gains EU MDR approval, expanding into new body areas and boosting investor confidence with a S&P BBB rating upgrade, positioning it for growth in the booming aesthetics market.
4 minutes to read
Galderma Group AG Exceeds Expectations with Record Q1 Sales and Strategic Growth Initiatives
Galderma Group AG reported record first quarter net sales of $1.129 billion, exceeding expectations and solidifying its position as a leader in the dermatology category.
2 minutes to read
Galderma Group AG Exceeds Expectations with Record Q1 Sales Growth
Galderma Group AG exceeded expectations with a 5.4% increase in sales for the first quarter of 2025, driven by strong product demand and new launches, including the “Scratch Resistance” campaign for NEMLUVIO.
2 minutes to read